Levopa Tablet 250 mg+25 mg combines Levodopa and Carbidopa, forming a cornerstone therapy for the management of Parkinson’s disease and parkinsonian syndromes. Levodopa is a precursor of dopamine, a neurotransmitter essential for controlling movement, which is deficient in patients with Parkinson’s disease. Carbidopa is a peripheral dopa-decarboxylase inhibitor that prevents the premature conversion of Levodopa into dopamine outside the brain, allowing more Levodopa to reach the central nervous system and reducing peripheral side effects.

This combination therapy effectively improves motor function, reduces rigidity, tremor, and bradykinesia, and enhances the overall quality of life in patients with Parkinson’s disease. By optimizing dopamine levels in the brain, Levopa Tablet 250 mg+25 mg helps restore motor control and alleviate the debilitating symptoms associated with dopamine deficiency.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Levopa Tablet 250 mg+25 mg is indicated for:

• Treatment of Parkinson’s disease

• Management of parkinsonian syndromes

• Relief of motor symptoms such as tremors, rigidity, bradykinesia, and postural instability

• Adjunct therapy in patients inadequately controlled with other anti-Parkinson medications

This medication is not indicated for the treatment of non-parkinsonian tremors or secondary movement disorders unrelated to dopamine deficiency.

Therapeutic Class

Anti-Parkinson agent (dopaminergic therapy)

Pharmacology

Levodopa crosses the blood-brain barrier and is converted into dopamine by the enzyme dopa-decarboxylase in the central nervous system. Increased dopamine concentrations help restore the balance between dopamine and acetylcholine in the basal ganglia, improving motor control and reducing Parkinsonian symptoms.

Carbidopa inhibits peripheral dopa-decarboxylase, reducing the conversion of Levodopa to dopamine outside the brain. This minimizes common side effects such as nausea, vomiting, and cardiovascular reactions, while increasing the amount of Levodopa available for the brain.

The combination allows for lower doses of Levodopa to achieve therapeutic effects, reducing long-term complications such as dyskinesia and motor fluctuations.

Dosage & Administration

Adults:

• Initial dose: One tablet (250 mg Levodopa + 25 mg Carbidopa) 2–3 times daily

• Dose may be gradually increased according to response and tolerance

• Maximum dose should be individualized based on clinical effect

Administration Instructions:

• Take orally with a glass of water

• Can be taken with or without food; high-protein meals may reduce absorption

• Swallow tablets whole; do not crush or chew

Pediatric Use:

• Use in children should be determined by a specialist, as safety and efficacy are less established

Precautions

• Monitor for orthostatic hypotension, dyskinesias, or psychiatric symptoms

• Use cautiously in patients with cardiac, hepatic, or renal disorders

• Abrupt discontinuation may exacerbate Parkinsonian symptoms or precipitate neuroleptic malignant syndrome

• Avoid concurrent use with non-selective MAO inhibitors

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

Common side effects include:

• Nausea and vomiting

• Dizziness and orthostatic hypotension

• Dyskinesias or involuntary movements

• Sleep disturbances, insomnia, or vivid dreams

• Psychiatric effects: hallucinations, confusion, or mood changes

Long-term use may lead to motor fluctuations (“on-off” phenomena) and peak-dose dyskinesias.

Use in Pregnancy and Lactation

Levodopa/Carbidopa should be used during pregnancy only if the benefits outweigh potential risks. Lactating mothers should avoid breastfeeding while on therapy.

Storage

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.

Levopa Tablet 250 mg+25 mg provides effective dopamine replacement therapy for Parkinson’s disease, improving motor function, reducing symptoms, and enhancing quality of life for patients with chronic neurological conditions.